Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Can PET imaging tell us what's the matter with the gray matter in multiple sclerosis?
Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica.
Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone.
Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis.
Bioinformatics challenges for genome-wide association studies.
Compassionate Use Programme Update
Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort.
Transcranial direct current stimulation (tDCS) for fatigue in multiple sclerosis.
A comparison of 12 weeks of pilates and aquatic training on the dynamic balance of women with mulitple sclerosis.
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
Cannabis and Cannabinoids (PDQ®)
Soluble adenylyl cyclase is necessary and sufficient to overcome the block of axonal growth by myelin-associated factors.
Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS.
Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action.
Effects of early IL-17A neutralization on disease induction in a primate model of experimental autoimmune encephalomyelitis.
How to treat tumefactive demyelinating disease?
Orbital Doppler evaluation of blood flow velocities in optic neuritis.
Expression of Ccl11 Associates with Immune Response Modulation and Protection against Neuroinflammation in Rats.
Animal models of multiple sclerosis: the good, the bad and the bottom line.
Cortical pathology in multiple sclerosis: experimental approaches to studies on the mechanisms of demyelination and remyelination.
[Optic neuritis: diagnosis, treatment and clinical implications].
Ozone autohemotherapy induces long-term cerebral metabolic changes in multiple sclerosis patients.
Neurotrophic factors and their effects in the treatment of multiple sclerosis.
Aspirin and multiple sclerosis.
Pages
« first
‹ previous
…
223
224
225
226
227
228
229
230
231
…
next ›
last »